PLEASANTON, Calif., Sept. 17, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) today announced the immediate availability of its Evie Ring, the first smart ring designed specifically for women. The ring features the same industry-first, award-winning open design that accommodates fluctuations in finger size, and is accompanied by an updated app that enhances users' ability to track and understand key metrics vital to their health and wellness.
Relaunching after a hiatus to address initial customer feedback and supply chain challenges, the updated app notably includes the ability to generate deeper personalized health insights through improved AI-based pattern recognition. This upgrade augments a trend analysis feature that sets Evie apart from every other wearable on the market.
Instead of simply reporting health data in daily or weekly graphs, Evie's custom insights engine identifies patterns over time, including correlations between menstrual cycle, heart health, sleep, mood and energy as well as progress toward user-defined goals. Findings such as inconsistent sleep schedules, an increase in restless nights, cycle insights and changes in heart rate variability are shared in the app's Notifications feature, eliminating the need for wearers to analyze weeks or months of data on their own. These insights also explain possible causes, impacts and solutions, helping users understand how they are feeling and, in some cases, suggesting they make adjustments or seek medical advice.
Evie utilizes a similar big-picture strategy in its unique Daily Summary data display, which dynamically shows the user's progress toward daily steps, active minutes, calorie burn, sleep and mood goals in a single graphic rather than in individual activity and performance scores used by other wearables. This approach enables users to easily track all goals in real time and provides an easy-to-understand snapshot of each day's activity and recovery, avoiding the time and effort required to review multiple data sources.
Other upgrades in the latest Evie release include:
Additional upgrades in development include:
The Evie Ring is scratch-resistant, has 4+ days of battery life, and recharges in just 60 minutes with the included charger. It is available exclusively through www.eviering.com in gold, rose gold and silver finishes and in sizes 5-12 with an optional complimentary sizing kit for those who don't know their ring size. It costs $269 with no subscription fees.
About Movano Health
Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health, maker of the Evie Ring (www.eviering.com), is developing a suite of purpose-driven healthcare solutions to bring medical-grade data to the forefront of wearables. Featuring modern and flexible form factors, Movano Health's devices offer an innovative approach to delivering trusted data to both customers and enterprises, capturing a comprehensive picture of an individual's health data and uniquely translating it into personalized and intelligent insights.
Movano Health's proprietary technologies and wearable medical device solutions will soon enable the use of data as a tool to proactively monitor and manage health outcomes across a number of patient populations that exist in healthcare. For more information on Movano Health, visit https://movanohealth.com/.
Forward Looking Statements
This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding plans with respect to the commercial launches of the Evie Ring and EvieMED; our expectations regarding potential commercial opportunities; planned cost-cutting initiatives; anticipated FDA clearance decisions with respect to our products; expected future operating results; product development and features, product releases, clinical trials and regulatory initiatives; our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Last Trade: | US$5.75 |
Daily Change: | 2.64 84.89 |
Daily Volume: | 34,475 |
Market Cap: | US$38.120M |
December 02, 2024 November 07, 2024 September 03, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB